Literature DB >> 17623590

Rare among the rarities--recurrent insulinoma.

Aisha Sheikh1, Lubna Zuberi, Naeemul Haque.   

Abstract

A patient with recurrent insulinoma without co-existing multiple endocrine neoplasia syndrome is described. In a 32-year-old man with recurrent episodes of symptomatic hypoglycemia, the supervised fast showed high insulin (24.5 IU/ml) and C-peptide level (3.06 ng/ml) with low blood sugar (27 mg/dl). A 1 x 1.5 cm nodule from the lower part of pancreatic body was removed on exploratory laparotomy. Histopathology confirmed the diagnosis of islet cell tumor. After 11 years, he started experiencing symptomatic hypoglycemic episodes with inappropriately elevated serum insulin and C-peptide levels (2.2 ng/ml). On pancreatic angiography, a 16 x 11 mm size tumor blush was noted. Due to fibrosis from previous surgery, distal pancreatectomy along with splenectomy was done. Histopathology confirmed the diagnosis of insulinoma. On both occasions, workup for multiple endocrine neoplasia turned out to be negative. He was given small amounts of intermediate acting insulin in early postoperative period, which was discontinued shortly thereafter.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623590     DOI: 06.2007/JCPSP.364366

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  3 in total

1.  Insulinoma: a comprehensive summary of two cases.

Authors:  Pankaj Sharma; Sonia Sharma; Shivani Kalhan; Bhanu Pratap Singh; Sonam Sharma
Journal:  J Clin Diagn Res       Date:  2014-09-20

Review 2.  Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.

Authors:  Melpomeni Fani; Petra Kolenc Peitl; Irina Velikyan
Journal:  Pharmaceuticals (Basel)       Date:  2017-03-15

Review 3.  Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.

Authors:  Irina Velikyan; Olof Eriksson
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.